OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Mechanisms of Resistance to Antibody–Drug Conjugates
Rachel O. Abelman, Bogang Wu, Laura M. Spring, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1278-1278
Open Access | Times Cited: 52
Rachel O. Abelman, Bogang Wu, Laura M. Spring, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1278-1278
Open Access | Times Cited: 52
Showing 1-25 of 52 citing articles:
Mechanisms of Resistance to Antibody-Drug Conjugates
Rita Khoury, Khalil Saleh, Nadine Khalife, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9674-9674
Open Access | Times Cited: 51
Rita Khoury, Khalil Saleh, Nadine Khalife, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 11, pp. 9674-9674
Open Access | Times Cited: 51
Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 25
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 25
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Swapnali Parit, Ajit Manchare, Amol D. Gholap, et al.
International Journal of Pharmaceutics (2024) Vol. 659, pp. 124211-124211
Closed Access | Times Cited: 15
Swapnali Parit, Ajit Manchare, Amol D. Gholap, et al.
International Journal of Pharmaceutics (2024) Vol. 659, pp. 124211-124211
Closed Access | Times Cited: 15
Homogeneous multi-payload antibody–drug conjugates
Toby Journeaux, Gonçalo J. L. Bernardes
Nature Chemistry (2024) Vol. 16, Iss. 6, pp. 854-870
Closed Access | Times Cited: 13
Toby Journeaux, Gonçalo J. L. Bernardes
Nature Chemistry (2024) Vol. 16, Iss. 6, pp. 854-870
Closed Access | Times Cited: 13
Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance
Meiting Chen, Riqing Huang, R.C. Chen, et al.
The Oncologist (2024) Vol. 29, Iss. 8, pp. e957-e966
Open Access | Times Cited: 12
Meiting Chen, Riqing Huang, R.C. Chen, et al.
The Oncologist (2024) Vol. 29, Iss. 8, pp. e957-e966
Open Access | Times Cited: 12
Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Ling Zhou, Yunlong Lu, Wei Liu, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 10
Targeting PI3K/AKT/mTOR Signaling to Overcome Drug Resistance in Cancer
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 8
Muhammad Tufail, Wendong Wan, Canhua Jiang, et al.
Chemico-Biological Interactions (2024) Vol. 396, pp. 111055-111055
Closed Access | Times Cited: 8
The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies
Puguang Yu, Chunming Zhu, Xiangyun You, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 8
Puguang Yu, Chunming Zhu, Xiangyun You, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 8
Nanoparticle innovations in targeted cancer therapy: advancements in antibody–drug conjugates
Magdi T. Abdelhamid, Al-Hassan Soliman, Hosam A. Saad, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 1
Magdi T. Abdelhamid, Al-Hassan Soliman, Hosam A. Saad, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Closed Access | Times Cited: 1
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?
Marina Popović, Tajana Silovski, Marija Križić, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8206-8206
Open Access | Times Cited: 17
Marina Popović, Tajana Silovski, Marija Križić, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 9, pp. 8206-8206
Open Access | Times Cited: 17
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
Liliana Ascione, Edoardo Crimini, Dario Trapani, et al.
The Oncologist (2023) Vol. 28, Iss. 11, pp. 944-960
Open Access | Times Cited: 17
Liliana Ascione, Edoardo Crimini, Dario Trapani, et al.
The Oncologist (2023) Vol. 28, Iss. 11, pp. 944-960
Open Access | Times Cited: 17
Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 1, pp. 208-224
Open Access | Times Cited: 7
Hiroki Goto, Yoshioki Shiraishi, Seiji Okada
Exploration of Targeted Anti-tumor Therapy (2024) Vol. 5, Iss. 1, pp. 208-224
Open Access | Times Cited: 7
Targeting Sphingosine-1-Phosphate Signaling in Breast Cancer
Masayuki Nagahashi, Yasuo Miyoshi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3354-3354
Open Access | Times Cited: 6
Masayuki Nagahashi, Yasuo Miyoshi
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3354-3354
Open Access | Times Cited: 6
Precision Medicine in Rheumatic Diseases: Unlocking the Potential of Antibody-Drug Conjugates
Zhiwen Huang, Zachary Braunstein, Jun Chen, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 4, pp. 579-598
Open Access | Times Cited: 6
Zhiwen Huang, Zachary Braunstein, Jun Chen, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 4, pp. 579-598
Open Access | Times Cited: 6
Antibody-drug conjugate adverse effects can be understood and addressed based on immune complex clearance mechanisms
Ronald P. Taylor, Margaret A. Lindorfer
Blood (2024) Vol. 144, Iss. 2, pp. 137-144
Closed Access | Times Cited: 6
Ronald P. Taylor, Margaret A. Lindorfer
Blood (2024) Vol. 144, Iss. 2, pp. 137-144
Closed Access | Times Cited: 6
Antibody-drug conjugates: the clinical development in gastric cancer
Yingze Zhu, Miao Zhou, Wenyue Kong, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 13
Yingze Zhu, Miao Zhou, Wenyue Kong, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 13
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
Jun He, Xianghua Zeng, Chunmei Wang, et al.
MedComm (2024) Vol. 5, Iss. 8
Open Access | Times Cited: 5
Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies
Seiichiro Takao, Hiroshi Fukushima, Aki Furusawa, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Seiichiro Takao, Hiroshi Fukushima, Aki Furusawa, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Recent advances of antibody-drug conjugates in treating breast cancer with different HER2 status
Yue Qiu, Y. Eric Shi, Zhujun Chao, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Yue Qiu, Y. Eric Shi, Zhujun Chao, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: A systematic review and updated meta-analysis
Isabella Michelon, Caio Castro, Thiago Madeira, et al.
Cancer Treatment Reviews (2025) Vol. 133, pp. 102882-102882
Closed Access
Isabella Michelon, Caio Castro, Thiago Madeira, et al.
Cancer Treatment Reviews (2025) Vol. 133, pp. 102882-102882
Closed Access
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access
Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models
Virginia Metrangolo, Mylan Blomquist, Ananya Dutta, et al.
Science Advances (2025) Vol. 11, Iss. 3
Open Access
Virginia Metrangolo, Mylan Blomquist, Ananya Dutta, et al.
Science Advances (2025) Vol. 11, Iss. 3
Open Access
Cathepsin B dependent Activatable Trigger Fluorophore (CAT-Fluor) for in situ functional imaging of antibody-drug conjugates
Jiangtao Ning, Yikai Shen, Hui Gao, et al.
Biosensors and Bioelectronics (2025), pp. 117184-117184
Closed Access
Jiangtao Ning, Yikai Shen, Hui Gao, et al.
Biosensors and Bioelectronics (2025), pp. 117184-117184
Closed Access
Synthesis and evaluation of KX-01 analogs with an exploration of linker attachment points for antibody-drug conjugates
Young‐Ho Oh, Dao T. T. An, Jaebeom Park, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130114-130114
Open Access
Young‐Ho Oh, Dao T. T. An, Jaebeom Park, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130114-130114
Open Access
